1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCongressionally Directed Medical Research Programs (CDMRP) -- Rare Cancers Research Program -- Concept Award is sponsored by Department of Defense. This award supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. It supports high-risk studies with the potential to reveal entirely new avenues for investigation.
Get alerted about grants like this
Save a search for “Department of Defense” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Rare Cancers Research Program, Congressionally Directed Medical Research Programs You are using an outdated browser. Please upgrade your browser to improve your experience. U.S. Department of War organization.
Due to routine system maintenance the CDMRP website will be unavailable from COB 24 April - 27 April COB.
DEPARTMENT OF WAR - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS Transforming Health Care through Innovative and Impactful Research Vision – To improve outcomes for people with rare cancers through discovery and community building, and expansion of knowledge across cancer landscape Mission – Promote rare cancers research by catalyzing knowledge building and enabling clinically impactful discoveries for the benefit of patients, Service Members, their Families, Veterans and/or the American public » Click on Image to View Summary Sheet A recent report from the American Cancer Society (ACS) found that one in five cancers diagnosed in the United States (U.S.) is a rare cancer, which is defined as an incidence of fewer than six cases per 100,000 people per year.
By this definition, around 200 forms of rare cancer compose around 20%-25% of all U.S. cancer diagnoses, which affect more than 400,000 Americans per year. There are a significant number of incidences of rare cancers in the U.S. military population. Over 60 forms of cancer disproportionately impact those who have served in the military, and 67% of them are rare cancers.
2017 data suggests that there are approximately 8,000 new cases of rare cancers in the U.S. Department of Veterans Affairs (VA) per year which account for 16% of all VA cancers. Rare cancers are traditionally understudied, reducing the progress of research and hindering decisions for patients, physicians, and policy makers.
For many rare cancers, research to identify causes or develop strategies for prevention and early detection is extremely difficult. In addition, rare cancers can be extremely challenging in terms of diagnosis, getting information about the cancer and caregiver assistance, fewer number of clinical trials, and lack of treatment options.
The U.S. Congress established the Rare Cancers Research Program (RCRP) in the Fiscal Year 2020 Department of Defense appropriation with an appropriation of $7. 5 million to address extreme challenges of people with rare cancers. RCRP will support research on the prevention, detection, diagnosis, and treatment of Service Members, Veterans, their families, and the American public.
RCRP will be managed by utilizing the CDMRP two-tiered review process . A stakeholders meeting was held on 17 April 2020, which brought experts from different subject areas together to identify knowledge gaps, outcome, and product needs for the state of the science and patient care.
At the stakeholders meeting, it was decided that CDMRP will follow the definition of rare cancer as an incidence of six or fewer cases per 100,000 people per year .
The RCRP focuses on the following areas: Biology: Identify disease-defining molecular pathways, cell context and microenvironment Preclinical Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness Therapy: Identify novel therapeutic strategies, including drug repurposing Artificial Intelligence (AI) and Machine Learning (ML) Model: Establish use of AI and/or ML tools in discovery, preclinical studies, and clinical trial readiness Platform Development: Develop platforms, such as tumor tissue repositories with clinical annotation, centralized databanks, patient registries with common data structure, research models, “omics” databases, and longitudinal studies of natural history and treatment response, for types or subtypes of rare cancers to allow sharing of data, biospecimens and resources American Cancer Society: https://www.
cancer. org/cancer/all-cancer-types.
html FY20 RARE CANCERS RESEARCH PROGRAM STAKEHOLDERS MEETING SUMMARY FY20 RARE CANCERS RESEARCH PROGRAM STAKEHOLDERS SURVEY SUMMARY Congressional Appropriations Recent Applications Recommended for Funding FY25 Peer Review Participants (pdf) A Catalyst for Collaboration [Click Image to Watch on DVIDS] National Institute of Health [Click Image to Watch on DVIDS] Chair, Department of Neurology Uniformed Services University of the Health Sciences Encouraging Multi-Institution Collaboration Across Cancer Types [Click Image to Watch on DVIDS] Broad Institute of Massachusetts Championing Rare Cancer Research as a Scientist and Survivor [Click Image to Watch on DVIDS] CDMRP Drives Discovery of New Treatments for Brain Cancers FY25 RCRP Recommended for Funding List CDMRP Funds Research to Accelerate Treatments for Rare Diseases to Support Warfighters and their Families A Catalyst for Collaboration (Watch on DVIDS) National Childhood Cancer Awareness Month: Advancing Research in More Than 13 Types of Childhood Cancers, Including Neuroblastoma Brain Cancer Awareness Month: A Mother's Story Head and Neck Cancer Awareness Month: Cholangiocarcinoma Awareness: A Rare Cancer Too Dangerous for a “Watch-and-Wait” Alpha-synuclein: Promising molecular test for Parkinson's disease Sarah Keitt: Feeling Empowered Alpha-synuclein: Promising molecular test for Parkinson's disease Click here to provide feedback/comments to the RCRP Last updated Wednesday, May 13, 2026
Based on current listing details, eligibility includes: Investigators at or above the level of postdoctoral fellow (or equivalent). Must address at least one of the RCRP focus areas. Clinical trials are not allowed. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $140,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
SBIR/STTR Programs (Defense Health Agency) is sponsored by Department of Defense (DOD) - Defense Health Agency (DHA). The DHA SBIR/STTR Programs fund biomedical and health-focused technologies that enhance medical readiness, clinical care delivery, force health protection, operational medicine, and military healthcare modernization. Priority research domains include digital health systems, AI-enabled triage, and physiological analytics.
Department of Defense Small Business Innovation Research (SBIR) Program is sponsored by U.S. Department of Defense. Invests in U.S. small businesses pursuing advanced R&D and high-impact technical solutions, including in cybersecurity, that can ultimately transition into operational defense systems, national-security environments, and commercial markets. The program is mission-driven and spans every major defense component.
The Department of Defense FY2026 Defense University Research Instrumentation Program (DURIP) provides funding for U.S. universities to acquire research equipment and instrumentation in areas important to national defense, including AI and machine learning hardware. The program is administered jointly by the Army Research Office (ARO), Office of Naval Research (ONR), and Air Force Office of Scientific Research (AFOSR), with approximately $34 million available and 95 awards anticipated. DURIP funds the acquisition of specialized computing hardware for AI/ML research (GPU clusters, TPUs, neuromorphic processors), robotics and autonomous systems testbeds, sensor arrays and data collection systems for machine learning training, high-performance computing infrastructure for defense-relevant AI research, and laboratory equipment for human-AI interaction studies. The program specifically supports equipment that enhances research-related education in DoD-priority disciplines. While general-purpose computing is not eligible, computing equipment directly supporting DoD-relevant AI research programs qualifies. No cost sharing is required.
SBIR/STTR Programs (Defense Health Agency) is sponsored by Department of Defense (DOD) - Defense Health Agency (DHA). The DHA SBIR/STTR Programs fund biomedical and health-focused technologies that enhance medical readiness, clinical care delivery, force health protection, operational medicine, and military healthcare modernization. Priority research domains include digital health systems, AI-enabled triage, and physiological analytics.
SBIR/STTR Programs is sponsored by Defense Health Agency (DHA). The DHA SBIR and STTR programs support U.S. small businesses in developing high-risk, high-impact medical materiel technologies with potential for wider commercialization, including those that could leverage AI for warfighter health and survival. This program seeks proposals that demonstrate both technical innovation and real clinical relevance in areas such as trauma care, battlefield triage, far-forward telemedicine, and digital health systems with AI-enabled triage.
Defense Health Agency (DHA) Small Business Innovation Research (SBIR) Program is sponsored by Defense Health Agency (DHA). The DHA SBIR program provides funding and support for small businesses to develop innovative healthcare technologies and solutions that benefit the military. It focuses on biomedical and health-focused technologies that enhance medical readiness, clinical care delivery, force health protection, operational medicine, and military healthcare modernization. Topics are aligned with real-world needs such as trauma care, telemedicine, infectious disease diagnostics, and wearable monitoring tools.